The French-Belgian medtech uses a portable headset to capture up to 800 infrared images per eye per second, extracting oculomotor biomarkers that can indicate Parkinson’s, Alzheimer’s, and multiple sclerosis years before clinical symptoms appear. It received CE certification in January 2025 and is targeting FDA clearance in 2026. neuroClues, a French-Belgian medtech company developing an […]

This story continues at The Next Web